<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS141081</article-id>
<article-id pub-id-type="doi">10.1101/2021.12.02.471030</article-id>
<article-id pub-id-type="archive">PPR428540</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Drug repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Chunlong</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yuyin</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Choza</surname>
<given-names>Juliana</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4845-4621</contrib-id>
<name>
<surname>Wang</surname>
<given-names>Jun</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Corresponding author: Jun Wang, Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States; Phone: +1-520-626-1366; Fax: 520-626-0749, <email>junwang@pharmacy.arizona.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>07</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="preprint">
<day>03</day>
<month>12</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">The global COVID-19 pandemic underscores the dire need of effective antivirals. Encouraging progress has been made in developing small molecule inhibitors targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and main protease (M<sup>pro</sup>). However, the development of papain-like protease (PL<sup>pro</sup>) inhibitors faces several obstacles. Nevertheless, PL<sup>pro</sup> represents a high-profile drug target given its multifaceted roles in viral replication. PL<sup>pro</sup> is involved in not only the cleavage of viral polyprotein but also modulation of host immune response. In this study, we conducted a drug-repurposing screening of PL<sup>pro</sup> against the MedChemExpress bioactive compound library and identified three hits, EACC, KY-226, and tropifexor, as potent PL<sup>pro</sup> inhibitors with IC<sub>50</sub> values ranging from 3.39 to 8.28 μM. The three hits showed dose-dependent binding to PL<sup>pro</sup> in the thermal shift assay. In addition, tropifexor inhibited the cellular PL<sup>pro</sup> activity in the FlipGFP assay with an IC<sub>50</sub> of 10.6 μM. Gratifyingly, tropifexor showed antiviral activity against SARS-CoV-2 in Calu-3 cells with an EC<sub>50</sub> of 4.03 μM, a 7.8-fold increase compared to GRL0617 (EC<sub>50</sub> = 31.4 μM). Overall, tropifexor represents a novel PL<sup>pro</sup> inhibitor that can be further developed as SARS-CoV-2 antivirals.</p>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>papain-like protease</kwd>
<kwd>PL<sup>pro</sup>
</kwd>
<kwd>antiviral</kwd>
<kwd>tropifexor</kwd>
<kwd>GRL0617</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p id="P2">The etiological agent of COVID-19 is SARS-CoV-2, a single-stranded, positive-sense RNA virus that belong to the β-coronavirus genera. Given the catastrophic impact of COVID-19 on public health and global economy, researchers around of the globe are working relentlessly to develop vaccines and antiviral drugs. This effort led to the approval of vaccines and antiviral drugs in record breaking speed. Two mRNA vaccines from Moderna and Pfizer, and one adenovirus vaccine from Johnson and Johnson were approved by FDA.<sup>
<xref ref-type="bibr" rid="R1">1</xref>
</sup>
</p>
<p id="P3">Although vaccines are the mainstay in combating the pandemic, antiviral drugs are nevertheless needed as complementary strategies. Vaccines are preventative, while antiviral drugs can be used for the treatment of COVID patients. In addition, the mRNA vaccines target the viral spike protein, which is prone to mutation as shown by the variants of concerns including the Delta variant and the most recent Omicron variant.<sup>
<xref ref-type="bibr" rid="R2">2</xref>
</sup> As a result, vaccines might need to be frequently updated to match the circulating strains. In comparison, small molecule antiviral drugs targeting the conserved viral proteins are expected to have broad-spectrum antiviral activity and a high genetic barrier to drug resistance. The viral RNA-dependent RNA polymerase (RdRp) inhibitor remdesivir is the first FDA-approved COVID drug.<sup>
<xref ref-type="bibr" rid="R3">3</xref>
</sup> In addition, the second RdRp inhibitor molnupirivir<sup>
<xref ref-type="bibr" rid="R4">4</xref>–<xref ref-type="bibr" rid="R6">6</xref>
</sup> and the main protease (M<sup>pro</sup>) inhibitor PF-07321332 (Paxlovid)<sup>
<xref ref-type="bibr" rid="R7">7</xref>
</sup> are likely to become the first oral COVID drugs.</p>
<p id="P4">Despite the encouraging progress, additional antiviral drugs with a novel mechanism of action are still in dire need to override the emergence of new mutations. They can be used either alone or in combination with existing RdRp inhibitors or M<sup>pro</sup> inhibitors to combat not only current COVID-19 pandemic, but also future coronavirus outbreaks.</p>
<p id="P5">SARS-CoV-2 expresses two viral proteases, the M<sup>pro</sup> and papain-like protease (PL<sup>pro</sup>), during viral replication. Both M<sup>pro</sup> and PL<sup>pro</sup> are cysteine proteases that mediate the cleavage of viral polyprotein during viral replication.<sup>
<xref ref-type="bibr" rid="R8">8</xref>
</sup> In addition, PL<sup>pro</sup> desregulates the host immune responses by cleaving ubiquitin and interferon-stimulated gene 15 protein (ISG15) from host proteins.<sup>
<xref ref-type="bibr" rid="R9">9</xref>
</sup> Therefore, inhibiting PL<sup>pro</sup> is a two-pronged approach in protecting host cells from viral infection.</p>
<p id="P6">PL<sup>pro</sup> is a 35-KDa domain of Nsp3, a 215-KDa multidomain protein that is a key component of the viral replication complex.<sup>
<xref ref-type="bibr" rid="R10">10</xref>
</sup> Compared to PL<sup>pro</sup> from SARS-CoV, SARS-CoV-2 PL<sup>pro</sup> displays decreased deubiquitination activity and enhanced deISGlyation activity.<sup>
<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R11">11</xref>
</sup>
</p>
<p id="P7">In contrast to M<sup>pro</sup>, PL<sup>pro</sup> is a more challenging drug target mainly for two reasons. First, the protein substrate of PL<sup>pro</sup> consists of LXGG.<sup>
<xref ref-type="bibr" rid="R12">12</xref>
</sup> Accordingly, there is a lack of drug binding pockets in the S1 and S2 subsites. As such, majority of reported PL<sup>pro</sup> inhibitors are non-covalent inhibitors that bind to the S3 and S4 subsites that are located more than 10 Å away from the catalytic cysteine C111.<sup>
<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R15">15</xref>
</sup> Second, PL<sup>pro</sup> bears structural similarities to human deubiquitinases and delSGylases,<sup>
<xref ref-type="bibr" rid="R16">16</xref>
</sup> which presents a challenge in developing selective PL<sup>pro</sup> inhibitors. Despite extensive high-throughput screening and lead optimization,<sup>
<xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R18">18</xref>
</sup> GRL0617 and its analogs remain the most potent PL<sup>pro</sup> inhibitors reported so far. To identify structurally novel PL<sup>pro</sup> inhibitors, we conducted a drug repurposing screening and identified EACC, KY-226, and tropifexor, as potent PL<sup>pro</sup> inhibitors with IC<sub>50</sub> values ranging from 3.39 to 8.28 μM. Their mechanism of action was further characterized in the thermal shift binding assay and the FlipGFP protease assay. Gratifyingly, tropifexor also had potent antiviral activity against SARS-CoV-2 in Calu-3 cells with an EC<sub>50</sub> of 4.03 μM. Overall, tropifexor represents a potent PL<sup>pro</sup> inhibitor with a novel scaffold that can be further developed as SARS-CoV-2 antivirals.</p>
<sec id="S1" sec-type="results | discussion">
<title>Results and Discussion</title>
<sec id="S2">
<title>High-throughput screening of SARS-CoV-2 PL<sup>pro</sup> inhibitors</title>
<p id="P8">Using the previously optimized FRET assay condition,<sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup> we performed a high-throughput screening of SARS-CoV-2 PL<sup>pro</sup> against the MedChemExpress bioactive compound library which consists of 9,791 compounds including FDA-approved drugs, clinical candidates, and natural products. All compounds were originally screened at 40 μM, and hits showing more than 50% inhibition were further titrated to determine the IC<sub>50</sub> values. GRL0617 was included as a positive control. In total, three compounds, EACC, KY-226, and tropifexor (<xref ref-type="fig" rid="F1">Figure 1A</xref>), were identified as positive hits with IC<sub>50</sub> values of 8.28, 3.39, and 5.11 μM, respectively (<xref ref-type="fig" rid="F1">Figure 1B</xref>). In comparison, the IC<sub>50</sub> value for the positive control GRL0617 was 1.66 μM (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Next, the broadspectrum activity of the three hits was tested against SARS-CoV PL<sup>pro</sup> (<xref ref-type="fig" rid="F1">Figure 1C</xref>) and MERS-CoV PL<sup>pro</sup> (<xref ref-type="fig" rid="F1">Figure 1D</xref>). It was found that EACC, KY-226, and tropifexor retained potent inhibition against SARS-CoV PL<sup>pro</sup> with IC<sub>50</sub> values of 6.28, 3.53, and 5.54 μM, respectively (<xref ref-type="fig" rid="F1">Figure 1C</xref>). In contrast, EACC and KY-226 were weak inhibitors of MERS-CoV PL<sup>pro</sup> with IC<sub>50</sub> values of 27.8 and 30.6 μM, while GRL0617 was inactive (IC<sub>50</sub> &gt; 60 μM) (<xref ref-type="fig" rid="F1">Figure 1D</xref>). Nevertheless, tropifexor showed higher potency against MERS-CoV PL<sup>pro</sup> with an IC<sub>50</sub> of 2.32 μM (<xref ref-type="fig" rid="F1">Figure 1D</xref>). The hits were further counter screened against the SARS-CoV-2 M<sup>pro</sup> to rule out promiscuous cysteine protease inhibitors.<sup>
<xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R22">22</xref>
</sup> It was found that EACC and KY-226 were not active (IC<sub>50</sub> ≥ 60 μM), while tropifexor had weak inhibition with an IC<sub>50</sub> of 43.65 μM, which corresponds to a selectivity index (SI) of 8.5 (<xref ref-type="fig" rid="F1">Figure 1E</xref>). These results suggest the inhibition of SARS-CoV-2 PL<sup>pro</sup> by tropifexor is specific. The inhibition of PL<sup>pro</sup>’s deubiquitination and deISGlyation activities were characterized using the Ub-AMC and ISG15-AMC substrates, respectively.<sup>
<xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R15">15</xref>
</sup> While EACC and KY-226 were inactive in inhibiting the deubiquitinase activity of PL<sup>pro</sup> (IC<sub>50</sub> &gt; 100 μM), tropifexor showed moderate activity with an IC<sub>50</sub> of 18.85 μM (<xref ref-type="fig" rid="F1">Figure 1F</xref>). Similarly, EACC and KY-226 were not active in inhibiting the deISGlyation activity of PL<sup>pro</sup> (IC<sub>50</sub> &gt; 80 μM), tropifexor showed does-dependent inhibition with an IC<sub>50</sub> of 27.22 μM (<xref ref-type="fig" rid="F1">Figure 1G</xref>). Overall, tropifexor appears to be the most promising hit with consistent inhibition against SARS-CoV-2, SARS-CoV, and MERS-CoV PL<sup>pro</sup>s. In addition, tropifexor also inhibited the deubiquitination and deISGlyation activities of SARS-CoV-2 PL<sup>pro</sup>, albeit at lower potency.</p>
</sec>
<sec id="S3">
<title>Pharmacological characterization of the hits in the thermal shift binding assay and the cell-based FlipGFP PL<sup>pro</sup> assay</title>
<p id="P9">The mechanism of action of EACC, KY-226, and tropifexor in inhibiting SARS-CoV-2 PL<sup>pro</sup> was further characterized in the thermal shift assay and the cell-based FlipGFP PL<sup>pro</sup> assay.<sup>
<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R20">20</xref>, <xref ref-type="bibr" rid="R23">23</xref>
</sup> Similar to the positive control GRL0617, all three hits displayed dose-dependent binding to PL<sup>pro</sup> as revealed by the enhanced melting temperatures with increasing drug concentration (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<p id="P10">Next, we tested the three hits in the FlipGFP PL<sup>pro</sup> assay.<sup>
<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R20">20</xref>
</sup> The FlipGFP PL<sup>pro</sup> was recently developed by us as a surrogate assay to quantify the cellular activity of PL<sup>pro</sup> inhibitors in the biological safety level 2 facility, and we have shown that there is positive correlation between the FlipGFP IC<sub>50</sub> values with the SARS-CoV-2 antiviral EC<sub>50</sub> values.<sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup> The FlipGFP assay is a virus free cell-based protease assay in which the 293T cells were transfected with PL<sup>pro</sup> and the GFP reporter. The GFP reporter consists of two fragments,<sup>
<xref ref-type="bibr" rid="R24">24</xref>–<xref ref-type="bibr" rid="R25">25</xref>
</sup> the β1-9 template, and the β10-11 strands that are constrained in the parallel inactive conformation through a PL<sup>pro</sup> substrate linker. Upon cleavage of the substrate linker, the β10 and β11 strands become parallel and can associate with the β1-9 template, leading to increased GFP signal. mCherry is included as an internal control to normalize transfection efficacy and compound cytotoxicity. In principle, the normalized GFP/mCherry ratio is proportional to the enzymatic activity of PL<sup>pro</sup>. The advantages of FlipGFP assay compared to the FRET assay is that it can rule out compounds that are cytotoxic, membrane impermeable, and having off-target effects that prevent cellular on-target engagement.<sup>
<xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R20">20</xref>
</sup>
</p>
<p id="P11">In the FlipGFP assay, the positive control GRL0617 showed dose-dependent inhibition with an IC<sub>50</sub> of 14.67 μM, while the negative control GC376 was not active (IC<sub>50</sub> &gt; 60 μM) (<xref ref-type="fig" rid="F3">Figure 3A, B</xref>). The results from EACC and KY-226 were not conclusive due to the cytotoxicity of the compounds. Tropifexor had an IC<sub>50</sub> of 10.60 μM, but a low selectivity index (CC<sub>50</sub> = 29.77 μM, SI = 2.8) (<xref ref-type="fig" rid="F3">Figure 3A, B</xref>). In summary, the FlipGFP assay results suggest tropifexor might have antiviral activity against SARS-CoV-2.</p>
</sec>
<sec id="S4">
<title>Antiviral activity of hits against SARS-CoV-2 in Calu-3 cells</title>
<p id="P12">The antiviral activity of EACC, KY-226, and tropifexor in inhibiting SARS-CoV-2 replication in Calu-3 cells was tested using the immunofluorescence assay (<xref ref-type="fig" rid="F4">Figure 4</xref>). Calu-3 is TMPRSS2-positive and is a close mimetic of the human respiratory epithelial cells,<sup>
<xref ref-type="bibr" rid="R26">26</xref>
</sup> enabling it a widely accepted cell line for SARS-CoV-2 studies.<sup>
<xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R27">27</xref>
</sup> The positive control GRL0617 had an EC<sub>50</sub> of 31.4 μM (<xref ref-type="fig" rid="F4">Figure 4A</xref>). EACC did not show antiviral activity at non-toxic drug concentration (EC<sub>50</sub> &gt; 35 μM, CC<sub>50</sub> = 35.29 μM) (<xref ref-type="fig" rid="F4">Figure 4B</xref>). Gratifyingly, both KY-226 and tropifexor had improved antiviral activity against SARS-CoV-2 with EC<sub>50</sub> values of 25.0 (<xref ref-type="fig" rid="F4">Figure 4C</xref>) and 4.03 μM (<xref ref-type="fig" rid="F4">Figure 4D</xref>), respectively. While KY-226 had a low selectivity index (SI = 1.65), tropifexor had a moderate selectivity window (SI = 6.97) and the observed antiviral activity was clearly not caused by the cytotoxicity of the compound.</p>
</sec>
<sec id="S5">
<title>Molecular docking of EACC, KY-226, and tropifexor in SARS-CoV-2 PL<sup>pro</sup>
</title>
<p id="P13">To gain insights of the binding mode of the three hits, we performed molecular docking with Schrödinger Glide using the wild-type SARS-CoV-2 PL<sup>pro</sup> structure we recently solved (PDB: 7JRN).<sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup> EACC, KY-226 and tropifexor all fit snuggly into the U-shape binding pocket that is covered by the BL2 loop where GRL0617 binds (<xref ref-type="fig" rid="F5">Figure 5A</xref>). EACC forms two hydrogen bonds with PL<sup>pro</sup>, one from the EACC carbonyl with the Gln269 main chain amide NH, and another from the EACC imide NH with the Asp164 side chain carboxylate (<xref ref-type="fig" rid="F5">Figure 5B</xref>). In addition, the nitro-thienyl ring forms a <bold>π-π</bold> interaction with the Tyr268 side chain phenol. For KY-226, the benzene ring in the biphenyl substitution similarly forms a π-π interaction with the Tyr268 side chain phenol. The sulfone from KY-226 forms a hydrogen bond with the Arg166 side chain guanidine NH (<xref ref-type="fig" rid="F5">Figure 5C</xref>). The carboxylate from tropifexor forms an ionic bond with the Lys157 side chain ammonium (<xref ref-type="fig" rid="F5">Figure 5D</xref>). The docking poses might provide a guidance for the following lead optimization.</p>
</sec>
</sec>
<sec id="S6" sec-type="conclusions">
<title>Conclusion</title>
<p id="P14">Although PL<sup>pro</sup> is a validated antiviral drug target, the development of PL<sup>pro</sup> inhibitors falls behind M<sup>pro</sup> and RdRp inhibitors. As of date, no PL<sup>pro</sup> inhibitors have been advanced to the <italic>in vivo</italic> animal model studies yet. The naphthalene compounds such as GRL0617 and its analogs are the only class of validated PL<sup>pro</sup> inhibitors with antiviral activity against SARS-CoV-2. However, the low metabolic stability of this series of compounds might prevent its further development.<sup>
<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R28">28</xref>
</sup> In this study, we aimed to identify structurally novel PL<sup>pro</sup> inhibitors that can serve as starting points for further optimization. Through screening the MedChemExpress bioactive compound library, three hits EACC, KY-226, and tropifexor were identified as SARS-CoV-2 PL<sup>pro</sup> inhibitors with IC<sub>50</sub> values in the single digit micromolar range. Among the three hits, tropifexor appears to be the most promising hit as it also showed potent inhibition against SARS-CoV PL<sup>pro</sup> (IC<sub>50</sub> = 5.54 μM) and MERS-CoV PL<sup>pro</sup> (IC<sub>50</sub> = 2.32 μM). Tropifexor is a highly potent agonist of the farnesoid X receptor and is currently undergoing phase II clinical trial for nonalcoholic steatohepatitis (NASH) and liver fibrosis.<sup>
<xref ref-type="bibr" rid="R29">29</xref>
</sup> In addition to the inhibition of PL<sup>pro</sup> mediated cleavage of viral polyprotein substrate, tropifexor also inhibited the deubiquitination and deISGlation activities of SARS-CoV-2 PL<sup>pro</sup>.</p>
<p id="P15">Consistent with the enzymatic inhibition, tropifexor showed dose-dependent stabilization of SARS-CoV-2 PL<sup>pro</sup> in the thermal shift binding assay. Importantly, tropifexor displayed cellular PL<sup>pro</sup> inhibitory activity in the FlipGFP assay and the antiviral activity against SARS-CoV-2 in Calu-3 cells. Although the low selectivity index (SI = 6.97) of tropifexor in the antiviral assay prevents its direct repurposing as a SARS-CoV-2 antiviral, the discovery of tropifexor as a novel PL<sup>pro</sup> inhibitor provides an additional scaffold for further medicinal chemistry optimization.</p>
</sec>
<sec id="S7" sec-type="materials | methods">
<title>Materials and Methods</title>
<sec id="S8">
<title>Protein Expression and Purification</title>
<p id="P16">Detailed expression and purification procedures untagged SARS-CoV-2 PL<sup>pro</sup> and SARS-CoV-2 M<sup>pro</sup> were described in our previous publications.<sup>
<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R30">30</xref>
</sup> SARS-CoV papain-like protease gene (ORF 1ab 1541‒1855) (accession # AEA10621.1) from strain SARS coronavirus MA15 with <italic>E. coli</italic> codon optimization in the pET28b-(+) vector was ordered from GenScript. Then the SARS-CoV PL<sup>pro</sup> gene (ORF 1ab 1541−1855) was subcloned from the pET28b-(+) to pE-SUMO vector according to the manufacturer’s protocol (LifeSensors Inc., Malvern, PA). The forward primer with the Bsa I site is GCGGTCTCAAGGTGAGGTGAAGACCATCAAAGTGTTCACCACC; the reverse primer with a Bsa I site is GCGGTCTCTCTAGATTATTTAATGGTGGTGGTATAGCTGGTTTCCTTGTAG. The expression and purification protocol of SARS-CoV PL<sup>pro</sup> is identical to SARS CoV-2 PL<sup>pro</sup>.<sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup>
</p>
<p id="P17">MERS-CoV PL<sup>pro</sup> gene (ORF 1ab 1482-1803) (accession # <underline>KY581684</underline>) from strain MERS coronavirus Hu/UAE_002_2013 with <italic>E. coli</italic> codon optimization in the pET28b-(+) vector was ordered from GenScript. Then MERS-CoV PL<sup>pro</sup> gene (ORF 1ab 1482-1803) was subclone into pE-SUMO vector with the pair primers: GCGGTCTCAAGGTCAGCTGACCATCGAGGTGCTGGTTACCGTGG and GCGGTCTCTCTAGATTAGTTGCAATCGCTGCTATATTTTTGACCCGGGAAC. The expression and purification protocol of MERS-CoV papain-like protease is identical to SARS CoV-2 PL<sup>pro</sup>.<sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup>
</p>
</sec>
<sec id="S9">
<title>FRET substrate synthesis</title>
<p id="P18">The SARS-CoV-2 PL<sup>pro</sup> FRET substrate 1 is Dabcyl-FTLRGG/APTKV(Edans); this substrate was also used as SARS-CoV PL<sup>pro</sup> and MERS-CoV PL<sup>pro</sup> substrates. SARS-CoV-2 M<sup>pro</sup> FRET substrate 2 is Dabcyl-KTSAVLQ/SGFRKME- (Edans). These FRET substrates were synthesized by solid-phase synthesis through iterative cycles of coupling and deprotection using the previously optimized procedure.<sup>
<xref ref-type="bibr" rid="R31">31</xref>
</sup> Ub-AMC and ISG15-AMC were purchased from BostonBiochem (catalog no. U-550-050 and UL-553-050, respectively).</p>
</sec>
<sec id="S10">
<title>Enzymatic Assays</title>
<p id="P19">The high-throughput screening was carried out in 384-well format as described previously.<sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup> The bioactive compound library consisting of 9,791 compounds was purchased from MedChemExpress (catalog no. HY-L001). The enzymatic reactions for SARS-CoV-2, SARS-CoV, MERS-CoV PL<sup>pro</sup>s were carried out in reaction buffer consisting of 50 mM HEPES pH 7.5, 5 mM DTT and 0.01% Triton X-100. For the IC<sub>50</sub> measurement with FRET peptide-Edans substrate, the reaction was carried out in 96-well format with 100 μl reaction volume. SARS-CoV-2 PL<sup>pro</sup> (200 nM) SARS-CoV PL<sup>pro</sup> (200 nM) or MERS-CoV PL<sup>pro</sup> (2 μM) was pre-incubated with various concentrations of testing compounds at 30 °C for 30 min before the addition of FRET-peptide substrate to initiate the reaction. The reaction was monitored in a Cytation 5 image reader with filters for excitation at 360/40 nm and emission at 460/40 nm at 30 °C for 1 h. The initial enzymatic reaction velocity was calculated from the initial 10 min enzymatic reaction via a linear regression function and was plotted against the substrate concentrations in Prism 8 with a four-parameter dose-response function. For the IC<sub>50</sub> measurements with Ub-AMC or ISG15-AMC substrate, the reaction was carried out in 384-well format in 50 μl reaction volume. In the Ub-AMC cleavage assay, the final SARS-CoV-2 PL<sup>pro</sup> concentration is 50 nM, and substrate Ub-AMC concentration is 2.5 μM. IN the ISG15-AMC assay, the final SARS-CoV-2 PL<sup>pro</sup> concentration is 2 nM, and substrate ISG15-AMC concentration is 0.5 μM. The SARS-CoV-2 M<sup>pro</sup> enzymatic assays were carried out in the reaction buffer containing 20 mM HEPES pH 6.5, 120 mM NaCl, 0.4 mM EDTA, 20% glycerol, and 4 mM DTT as described previously.<sup>
<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R32">32</xref>
</sup>
</p>
</sec>
<sec id="S11">
<title>Differential Scanning Fluorimetry (DSF)</title>
<p id="P20">The thermal shift binding assay (TSA) was carried out using a Thermo Fisher QuantStudio 5 Real-Time PCR system as described previously.<sup>
<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R30">30</xref>
</sup> Briefly, 4 μM SARS-CoV-2 PL<sup>pro</sup> protein in PL<sup>pro</sup> reaction buffer (50 mM HEPES pH 7.5, 5 mM DTT and 0.01% Triton X-100) was incubated with various concentrations of testing compounds at 30 °C for 30 min. 1× SYPRO orange dye was added, and the fluorescence of each well was monitored under a temperature gradient range from 20 to 90 °C with 0.05 °C/s incremental step. The melting temperature (Tm) was calculated as the mid-log of the transition phase from the native to the denatured protein using a Boltzmann model in Protein Thermal Shift Software v1.3.</p>
</sec>
<sec id="S12">
<title>Cell-Based FlipGFP PL<sup>pro</sup> Assay</title>
<p id="P21">Plasmid pcDNA3-PLpro-flipGFP-T2A-mCherry was constructed from pcDNA3-TEV-flipGFP-T2A-mCherry.<sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup> SARS-CoV-2 PL<sup>pro</sup> expression plasmid pcDNA3.1-SARS2 PL<sup>pro</sup> was ordered from Genscript (Piscataway NJ) with codon optimization. For transfection, 293T cells were seeded into 96-well Greiner plate (catalog no. 655090) to overnight with 70‒90% confluency. 50 ng of pcDNA3-PLPro-flipGFP-T2A-mCherry plasmid and 50 ng of protease expression plasmid pcDNA3.1-PL<sup>pro</sup> were added to each well in the presence of transfection reagent TransIT-293 (Mirus) according to manufacturer’s protocol. Three hours after transfection, 1 μL of testing compound was added to each well at 100-fold dilution. Images were acquired 2 days after transfection with a Cytation 5 imaging reader (Biotek) GFP and mCherry channels and were analyzed with Gen5 3.10 software (Biotek). SARS-CoV-2 PL<sup>pro</sup> protease activity was calculated by the ratio of GFP signal over the mCherry signal. The FlipGFP PL<sup>pro</sup> assay IC<sub>50</sub> value was determined by plotting the GFP/ mCherry signal over the compound concentration with a four-parameter dose−response function in Prism 8. The mCherry signal alone was utilized to evaluate the transfection efficiency and compound cytotoxicity.</p>
</sec>
<sec id="S13">
<title>Molecular modeling of the binding of EACC, KY-226, and tropifexor to SARS-CoV-2 PL<sup>pro</sup>
</title>
<p id="P22">Docking was performed using Schrödinger Glide standard precision. The SARS-CoV-2 PL<sup>pro</sup> structure was downloaded from PDB code 7JRN. The final docking poses were generated in PyMOL. The protein electrostatistics surface was generated using the APBS Electrostatistics model in PyMOL.</p>
</sec>
</sec>
</body>
<back>
<ack id="S14">
<title>Acknowledgments</title>
<p>This research was partially supported by the National Institute of Allergy and Infectious Diseasess of Health (NIH) (grants AI147325, AI157046, and AI158775) and the Arizona Biomedical Research Commission Centre Young Investigator grant (ADHS18-198859) to J. W. The SARS-CoV-2 antiviral assay in Calu-3 cells was conducted by Drs. David Schultz and Sara Cherry at the University of Pennsylvania (USA) through the NIAID preclinical service under a non-clinical evaluation agreement.</p>
</ack>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P23">
<bold>Author Contributions</bold>
</p>
<p id="P24">J.W. and C.M. conceived and designed the study; C.M. performed the high-throughput screening, enzymatic assays, and thermal shift binding assay. Y. W. and J. C. helped with the protein expression and purification, and the enzymatic assays. J.W. wrote the manuscript with the input from C.M.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tregoning</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Flight</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Higham</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Pierce</surname>
<given-names>BF</given-names>
</name>
</person-group>
<article-title>Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape</article-title>
<source>Nat Rev Immunol</source>
<year>2021</year>
<volume>21</volume>
<issue>10</issue>
<fpage>626</fpage>
<lpage>636</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Carabelli</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Ludden</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reeve</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rambaut</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peacock</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>DL</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title>
<source>Nat Rev Microbiol</source>
<year>2021</year>
<volume>19</volume>
<issue>7</issue>
<fpage>409</fpage>
<lpage>424</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beigel</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Tomashek</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Zingman</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Kalil</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Hohmann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Luetkemeyer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kline</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir for the treatment of covid-19 — final report</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>383</volume>
<fpage>1813</fpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gralinski</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kovarova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dinnon</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Madden</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Krzystek</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>De</surname>
<given-names>C</given-names>
</name>
<name>
<surname>White</surname>
<given-names>KK</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801</article-title>
<source>Nature</source>
<year>2021</year>
<volume>591</volume>
<issue>7850</issue>
<fpage>451</fpage>
<lpage>457</lpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cox</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Plemper</surname>
<given-names>RK</given-names>
</name>
</person-group>
<article-title>Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets</article-title>
<source>Nat Microbiol</source>
<year>2021</year>
<volume>6</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>18</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheahan</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Pruijssers</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Agostini</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Leist</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Schafer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dinnon</surname>
<given-names>KH</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Stevens</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Chappell</surname>
<given-names>JD</given-names>
</name>
<etal/>
</person-group>
<article-title>An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice</article-title>
<source>Sci Transl Med</source>
<year>2020</year>
<volume>12</volume>
<issue>541</issue>
<elocation-id>eabb5883</elocation-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owen</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Allerton</surname>
<given-names>CMN</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Aschenbrenner</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Avery</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berritt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boras</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cardin</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Carlo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Coffman</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Dantonio</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>An oral SARS-CoV-2 M<sup>pro</sup>inhibitor clinical candidate for the treatment of COVID-19</article-title>
<source>Science</source>
<elocation-id>eabl4784</elocation-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chiaravalli</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gellenoncourt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brownridge</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bryne</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Daly</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Grauslys</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Agou</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>LA</given-names>
</name>
<etal/>
</person-group>
<article-title>Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<issue>1</issue>
<elocation-id>5553</elocation-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mukherjee</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Grewe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bojkova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bhattacharya</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Widera</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mehdipour</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Tascher</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Geurink</surname>
<given-names>PP</given-names>
</name>
<etal/>
</person-group>
<article-title>Papain-like protease regulates sars-cov-2 viral spread and innate immunity</article-title>
<source>Nature</source>
<year>2020</year>
<volume>587</volume>
<fpage>657</fpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baez-Santos</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>St John</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Mesecar</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds</article-title>
<source>Antiviral Res</source>
<year>2015</year>
<volume>115</volume>
<fpage>21</fpage>
<lpage>38</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klemm</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Calleja</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Allison</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Bernardini</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Kuchel</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Grohmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>ZY</given-names>
</name>
<etal/>
</person-group>
<article-title>Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2</article-title>
<source>EMBO J</source>
<year>2020</year>
<volume>39</volume>
<issue>18</issue>
<elocation-id>e106275</elocation-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rut</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zmudzinski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Patchett</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nayak</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Snipas</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>El Oualid</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Bekes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Drag</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>SK</given-names>
</name>
</person-group>
<article-title>Activity profiling and crystal structures of inhibitor-bound sars-cov-2 papain-like protease: A framework for anti-covid-19 drug design</article-title>
<source>Sci Adv</source>
<year>2020</year>
<volume>6</volume>
<fpage>42</fpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2</article-title>
<source>Cell Chem Biol</source>
<year>2021</year>
<volume>28</volume>
<issue>6</issue>
<fpage>855</fpage>
<lpage>865</lpage>
<elocation-id>e9</elocation-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ratia</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Alqarni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dubrovskyi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rong</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity</article-title>
<source>J Med Chem</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c01307</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lambrinidis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Townsend</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Szeto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ba</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gongora</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay</article-title>
<source>ACS Cent Sci</source>
<year>2021</year>
<volume>7</volume>
<issue>7</issue>
<fpage>1245</fpage>
<lpage>1260</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ratia</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kilianski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Baez-Santos</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Mesecar</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Structural basis for the ubiquitin-linkage specificity and deisgylating activity of sars-cov papain-like protease</article-title>
<source>PLoS Pathog</source>
<year>2014</year>
<volume>10</volume>
<elocation-id>e1004113</elocation-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<issue>1</issue>
<elocation-id>488</elocation-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osipiuk</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Azizi</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Dvorkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Endres</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jedrzejczak</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kathayat</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lisnyak</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Maki</surname>
<given-names>SL</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<issue>1</issue>
<elocation-id>743</elocation-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Choza</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays</article-title>
<source>Acta Pharm Sin, B</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1016/j.apsb.2021.10.026</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors</article-title>
<source>bioRxiv</source>
<year>2021</year>
<elocation-id>2021.11.04.467342</elocation-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Townsend</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lagarias</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Marty</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Kolocouris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors</article-title>
<source>ACS Pharmacol Transl Sci</source>
<year>2020</year>
<volume>3</volume>
<issue>6</issue>
<fpage>1265</fpage>
<lpage>1277</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2021</year>
<volume>118</volume>
<issue>8</issue>
<elocation-id>e2024420118</elocation-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Szeto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir</article-title>
<source>ACS Pharmacol Transl Sci</source>
<year>2021</year>
<volume>4</volume>
<issue>4</issue>
<fpage>1408</fpage>
<lpage>1421</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lidsky</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C-T</given-names>
</name>
<name>
<surname>Garcia-Knight</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nayak</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Andino</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shu</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Ethacridine inhibits SARS-CoV-2 by inactivating viral particles</article-title>
<source>PLos Pathog</source>
<year>2021</year>
<volume>17</volume>
<issue>9</issue>
<elocation-id>e1009898</elocation-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Froggatt</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Heaton</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Heaton</surname>
<given-names>NS</given-names>
</name>
</person-group>
<article-title>Development of a FluorescenceBased, High-Throughput SARS-CoV-2 3CL(pro) Reporter Assay</article-title>
<source>J Virol</source>
<year>2020</year>
<volume>94</volume>
<issue>22</issue>
<elocation-id>e01265-20</elocation-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kleine-Weber</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kruger</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Herrler</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Erichsen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schiergens</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Herrler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Nitsche</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<issue>2</issue>
<fpage>271</fpage>
<lpage>280</lpage>
<elocation-id>e8</elocation-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitamura</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Townsend</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ba</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Szeto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kukuljac</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors</article-title>
<source>J Med Chem</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00509</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Báez-Santos</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Barraza</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Agius</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Mielech</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Mesecar</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases</article-title>
<source>J Med Chem</source>
<year>2014</year>
<volume>57</volume>
<fpage>2393</fpage>
<lpage>2412</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tully</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Rucker</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Chianelli</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vidal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alper</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Mutnick</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bursulaya</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schmeits</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)</article-title>
<source>J Med Chem</source>
<year>2017</year>
<volume>60</volume>
<issue>24</issue>
<fpage>9960</fpage>
<lpage>9973</lpage>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Hurst</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Townsend</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Szeto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tarbet</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Marty</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease</article-title>
<source>Cell Res</source>
<year>2020</year>
<volume>30</volume>
<issue>8</issue>
<fpage>678</fpage>
<lpage>692</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cady</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>DeGrado</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Specific Binding of Adamantane Drugs and Direction of Their Polar Amines in the Pore of the Influenza M2 Transmembrane Domain in Lipid Bilayers and Dodecylphosphocholine Micelles Determined by NMR Spectroscopy</article-title>
<source>J Am Chem Soc</source>
<year>2011</year>
<volume>133</volume>
<issue>12</issue>
<fpage>4274</fpage>
<lpage>4284</lpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacco</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lagarias</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Townsend</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Dube</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kitamura</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hurst</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L</article-title>
<source>Sci Adv</source>
<year>2020</year>
<volume>6</volume>
<issue>50</issue>
<elocation-id>eabe0751</elocation-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Characterization of SARS-CoV-2 PL<sup>pro</sup> inhibitors identified from the high-throughput screening.</title>
<p>(A) Chemical structures of the positive control GRL0617 and the three hits EACC, KY-226, and tropifexor. (B) IC<sub>50</sub> curves of the hits in inhibiting SARS CoV-2 PL<sup>pro</sup> with the FRET peptide substrate 1. (C) IC<sub>50</sub> curves of the hits in inhibiting SARS CoV PL<sup>pro</sup> with the FRET peptide substrate 1. (D) IC<sub>50</sub> curves of the hits in inhibiting MERS-CoV PL<sup>pro</sup> with the FRET peptide substrate 1. (E) IC<sub>50</sub> curves of the hits in inhibiting SARS CoV-2 M<sup>pro</sup> with the FRET peptide substrate 2. (F) IC<sub>50</sub> curves of the hits in inhibiting SARS CoV-2 PL<sup>pro</sup> with the Ub-AMC substrate. (G) IC<sub>50</sub> curves of the hits in inhibiting SARS CoV-2 PL<sup>pro</sup> with the ISG15-AMC substrate. Please refer to the methods and materials section for assay conditions. Values represent the average ± standard deviation of three replicates.</p>
</caption>
<graphic xlink:href="EMS141081-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Thermal shift binding assay of SARS-CoV-2 PL<sup>pro</sup> protease against identified inhibitors. All inhibitors display dose-dependent melting temperature (T<sub>m</sub>) shift. Values represent the average ± standard deviation of three replicates.</p>
</caption>
<graphic xlink:href="EMS141081-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>FlipGFP SARS CoV-2 PL<sup>pro</sup> assay to determine cellular protease inhibitory activity of identified inhibitors.</title>
<p>(A) Representative images of FlipGFP-PL<sup>pro</sup> assay with increasing concentrations of GRL0617 (positive control), GC376 (negative control), EACC, KY-226, and tropifexor. GRL0617 showed does-dependent decrease of GFP signal with the increasing drug concentration, while almost no GFP signal change was observed with the increasing concentration of negative control compound GC376. (B) Dose‒response curves of the GFP/mCherry ratio with increasing drug concentrations. mCherry signal alone was used to calculate transfection efficiency and compound cytotoxicity. All three hits displayed significant cytotoxicity at high drug concentrations. Values represent the average ± standard deviation of three replicates.</p>
</caption>
<graphic xlink:href="EMS141081-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Antiviral activity of SARS-CoV-2 PL<sup>pro</sup> inhibitors GRL0617 (A), EACC(B), KY-226 (C), and tropifexor (D) against SARS-CoV-2 in Calu-3 cells. The results were quantified by immunofluorescence assay. Values represent the average ± standard deviation of three replicates.</p>
</caption>
<graphic xlink:href="EMS141081-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>Molecular docking of SARS-CoV-2 PL<sup>pro</sup> inhibitors GRL0617 (A), EACC(B), KY-226 (C), and tropifexor (D) in PL<sup>pro</sup> (PDB: 7JRN).</p>
</caption>
<graphic xlink:href="EMS141081-f005"/>
</fig>
</floats-group>
</article>
